Retatrutide investigational peptide undergoes metabolic research

Retatrutide, also known by the code name LY3437943, is an investigational synthetic peptide developed by Eli Lilly. It is a triple receptor agonist designed to mimic natural gut and pancreatic hormones by acting on GIP, GLP-1, and glucagon receptors simultaneously.

Scientific research is currently evaluating the substance for its potential metabolic applications, specifically regarding food regulation, sugar management, and weight control. While large-scale human results were published in the New England Journal of Medicine in 2023, the compound remains in the investigational stage and has not been approved by health authorities for human use.

Because it is not an approved medicine, retatrutide is currently available as a research-use-only compound, often supplied as a lyophilized powder for laboratory studies. Researchers emphasize that clinical trials are necessary to establish definitive data on safety, tolerability, and long-term effectiveness.